AU2021401741A1 - Macrocycles and their use - Google Patents
Macrocycles and their use Download PDFInfo
- Publication number
- AU2021401741A1 AU2021401741A1 AU2021401741A AU2021401741A AU2021401741A1 AU 2021401741 A1 AU2021401741 A1 AU 2021401741A1 AU 2021401741 A AU2021401741 A AU 2021401741A AU 2021401741 A AU2021401741 A AU 2021401741A AU 2021401741 A1 AU2021401741 A1 AU 2021401741A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- alkylene
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126722P | 2020-12-17 | 2020-12-17 | |
| US63/126,722 | 2020-12-17 | ||
| US202163279850P | 2021-11-16 | 2021-11-16 | |
| US63/279,850 | 2021-11-16 | ||
| US202163284789P | 2021-12-01 | 2021-12-01 | |
| US63/284,789 | 2021-12-01 | ||
| US202163289014P | 2021-12-13 | 2021-12-13 | |
| US63/289,014 | 2021-12-13 | ||
| PCT/US2021/063721 WO2022133037A1 (en) | 2020-12-17 | 2021-12-16 | Macrocycles and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021401741A1 true AU2021401741A1 (en) | 2023-06-29 |
| AU2021401741A9 AU2021401741A9 (en) | 2024-09-19 |
Family
ID=82058646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021401741A Pending AU2021401741A1 (en) | 2020-12-17 | 2021-12-16 | Macrocycles and their use |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240182487A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4262796A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023553835A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230121773A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021401741A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3202770A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL303419A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023007162A (cg-RX-API-DMAC7.html) |
| PY (1) | PY21110949A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI923651B (cg-RX-API-DMAC7.html) |
| UY (1) | UY39574A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022133037A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250022117A (ko) * | 2022-06-08 | 2025-02-14 | 블로썸힐 테라퓨틱스, 인크. | 인다졸 거대고리 화합물 및 그의 용도 |
| AU2023282906A1 (en) * | 2022-06-08 | 2024-11-28 | Blossomhill Therapeutics, Inc. | Indazole containing macrocycles and their use |
| CN119013283A (zh) * | 2022-07-27 | 2024-11-22 | 上海和誉生物医药科技有限公司 | 大环egfr抑制剂及其制备方法和药学上的应用 |
| JP2026507655A (ja) * | 2023-02-22 | 2026-03-04 | ユーハン・コーポレイション | Egfr阻害剤としての大環状アミノピリジン化合物 |
| JP2026507653A (ja) * | 2023-02-22 | 2026-03-04 | ユーハン・コーポレイション | Egfr阻害剤としての大環状アミノピリジン化合物 |
| CN120981466A (zh) * | 2023-02-22 | 2025-11-18 | 柳韩洋行 | 作为egfr抑制剂的大环氨基吡啶化合物 |
| WO2024209363A1 (en) | 2023-04-06 | 2024-10-10 | Pfizer Inc. | Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators |
| JP2026517554A (ja) * | 2023-05-02 | 2026-06-02 | ブロッサムヒル・セラピューティクス・インコーポレイテッド | 疾患の処置のためのegfr阻害剤 |
| JP2026521264A (ja) * | 2023-06-23 | 2026-06-29 | ブロッサムヒル・セラピューティクス・インコーポレイテッド | 大環状インダゾール化合物の併用療法 |
| TW202527935A (zh) * | 2023-12-07 | 2025-07-16 | 美商榮山醫藥股份有限公司 | 吲唑巨環多晶型物 |
| IL328856A (en) * | 2023-12-08 | 2026-08-01 | Blossomhill Therapeutics Inc | Indazole-based macrocyclic compounds |
| WO2025199438A1 (en) * | 2024-03-22 | 2025-09-25 | Blossomhill Therapeutics, Inc. | 7-azaindazole macrocycles and their use |
| WO2025245175A1 (en) * | 2024-05-22 | 2025-11-27 | Ajax Therapeutics, Inc. | Macrocyclic heteroaromatic inhibitors of jak2 |
| WO2026064346A1 (en) * | 2024-09-18 | 2026-03-26 | Blossomhill Therapeutics, Inc. | Tetracyclic-macrocycles and their use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3062B1 (ar) * | 2010-10-05 | 2017-03-15 | Lilly Co Eli | R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري |
| CA2863892C (en) * | 2012-03-06 | 2016-08-30 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| EP3333157B1 (en) * | 2015-08-07 | 2020-12-23 | Harbin Zhenbao Pharmaceutical Co., Ltd. | Vinyl compounds as fgfr and vegfr inhibitors |
| CN111269245B (zh) * | 2018-12-04 | 2021-08-27 | 杭州百新生物医药科技有限公司 | 一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途 |
| IL317393A (en) * | 2018-12-21 | 2025-02-01 | Revolution Medicines Inc | Compounds that participate in covalent bonds and their uses |
-
2021
- 2021-12-16 JP JP2023532465A patent/JP2023553835A/ja active Pending
- 2021-12-16 US US18/257,166 patent/US20240182487A1/en active Pending
- 2021-12-16 AU AU2021401741A patent/AU2021401741A1/en active Pending
- 2021-12-16 EP EP21907788.0A patent/EP4262796A4/en active Pending
- 2021-12-16 WO PCT/US2021/063721 patent/WO2022133037A1/en not_active Ceased
- 2021-12-16 IL IL303419A patent/IL303419A/en unknown
- 2021-12-16 MX MX2023007162A patent/MX2023007162A/es unknown
- 2021-12-16 CA CA3202770A patent/CA3202770A1/en active Pending
- 2021-12-16 TW TW110147239A patent/TWI923651B/zh active
- 2021-12-16 KR KR1020237021826A patent/KR20230121773A/ko active Pending
- 2021-12-17 PY PY202121110949A patent/PY21110949A/es unknown
- 2021-12-17 UY UY0001039574A patent/UY39574A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PY21110949A (es) | 2023-08-07 |
| TW202241911A (zh) | 2022-11-01 |
| WO2022133037A1 (en) | 2022-06-23 |
| EP4262796A1 (en) | 2023-10-25 |
| IL303419A (en) | 2023-08-01 |
| JP2023553835A (ja) | 2023-12-26 |
| MX2023007162A (es) | 2023-06-29 |
| TWI923651B (zh) | 2026-05-01 |
| EP4262796A4 (en) | 2025-04-02 |
| US20240182487A1 (en) | 2024-06-06 |
| KR20230121773A (ko) | 2023-08-21 |
| CA3202770A1 (en) | 2022-06-23 |
| AU2021401741A9 (en) | 2024-09-19 |
| UY39574A (es) | 2022-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4262796A1 (en) | Macrocycles and their use | |
| AU2015209239B2 (en) | Diaryl macrocycles as modulators of protein kinases | |
| WO2023173014A1 (en) | Kras inhibitors and their use | |
| WO2023173017A1 (en) | Kras inhibitors for treating disease | |
| AU2024273014A1 (en) | Fused ring kras inhibitors for treating disease | |
| WO2023173016A1 (en) | Kras inhibitors for treating disease | |
| JP7713619B2 (ja) | 大員環分子およびそれらの使用 | |
| EP4536224A1 (en) | Indazole containing macrocycles and their use | |
| EP4536225A1 (en) | Indazole macrocycles and their use | |
| CA3246487A1 (en) | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | |
| IL324276A (en) | Egfr inhibitors for treating disease | |
| CN116635076A (zh) | 大环化合物及其用途 | |
| WO2025199438A1 (en) | 7-azaindazole macrocycles and their use | |
| WO2026064346A1 (en) | Tetracyclic-macrocycles and their use | |
| WO2026101971A2 (en) | Egfr inhibitors for treating disease | |
| WO2025212729A1 (en) | Macrocyclic compounds and their use | |
| WO2025235733A1 (en) | Bis-bicycloheteroaryl macrocycles and their use | |
| WO2025122859A1 (en) | Indazole-based macrocyclic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished |